These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 3045221)

  • 1. Clinical and biological effects of recombinant interferon-beta administered intravenously daily in phase I trial.
    Borden EC; Hawkins MJ; Sielaff KM; Storer BM; Schiesel JD; Smalley RV
    J Interferon Res; 1988 Jun; 8(3):357-66. PubMed ID: 3045221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-beta serine.
    Goldstein D; Sielaff KM; Storer BE; Brown RR; Datta SP; Witt PL; Teitelbaum AP; Smalley RV; Borden EC
    J Natl Cancer Inst; 1989 Jul; 81(14):1061-8. PubMed ID: 2472488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A direct comparison of biological response modulation and clinical side effects by interferon-beta ser, interferon-gamma, or the combination of interferons beta ser and gamma in humans.
    Schiller JH; Storer B; Paulnock DM; Brown RR; Datta SP; Witt PL; Borden EC
    J Clin Invest; 1990 Oct; 86(4):1211-21. PubMed ID: 2120284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological and clinical effects of interferon-beta ser at two doses.
    Borden EC; Rinehart JJ; Storer BE; Trump DL; Paulnock DM; Teitelbaum AP
    J Interferon Res; 1990 Dec; 10(6):559-70. PubMed ID: 2086672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of recombinant interferon-beta in patients with advanced malignant disease.
    Ravandi F; Estrov Z; Kurzrock R; Breitmeyer JB; Maschek BJ; Talpaz M
    Clin Cancer Res; 1999 Dec; 5(12):3990-8. PubMed ID: 10632330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of interferon-beta-serine in metastatic renal cell carcinoma.
    Kinney P; Triozzi P; Young D; Drago J; Behrens B; Wise H; Rinehart JJ
    J Clin Oncol; 1990 May; 8(5):881-5. PubMed ID: 2332772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I/II trial of interferon-beta-serine in patients with renal cell carcinoma: immunological and biological effects.
    Rinehart JJ; Young D; Laforge J; Colborn D; Neidhart JA
    Cancer Res; 1987 May; 47(9):2481-5. PubMed ID: 3567933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of recombinant beta ser 17 interferon in the treatment of cancer.
    Sarna G; Pertcheck M; Figlin R; Ardalan B
    Cancer Treat Rep; 1986 Dec; 70(12):1365-72. PubMed ID: 3791249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological and clinical effects of the combination of beta- and gamma-interferons administered as a 5-day continuous infusion.
    Schiller JH; Storer B; Witt PL; Nelson B; Brown RR; Horisberger M; Grossberg S; Borden EC
    Cancer Res; 1990 Aug; 50(15):4588-94. PubMed ID: 2114942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth inhibitory effects of interferon-beta but not interferon-alpha on human glioma cells: correlation of receptor binding, 2',5'-oligoadenylate synthetase and protein kinase activity.
    Rosenblum MG; Yung WK; Kelleher PJ; Ruzicka F; Steck PA; Borden EC
    J Interferon Res; 1990 Apr; 10(2):141-51. PubMed ID: 2140395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of a combination of interferon-beta ser and interferon-gamma in patients with advanced malignant melanoma.
    Schiller JH; Storer B; Bittner G; Willson JK; Borden EC
    J Interferon Res; 1988 Oct; 8(5):581-9. PubMed ID: 3148669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of combinations of recombinant interferons beta(ser) and gamma in patients with advanced malignancy.
    Schiller JH; Storer B; Willson JK; Borden EC
    Cancer Treat Rep; 1987 Oct; 71(10):945-52. PubMed ID: 3115570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beta-interferon therapy in patients with poor-prognosis Kaposi sarcoma related to the acquired immunodeficiency syndrome (AIDS). A phase II trial with preliminary evidence of antiviral activity and low incidence of opportunistic infections.
    Miles SA; Wang HJ; Cortes E; Carden J; Marcus S; Mitsuyasu RT
    Ann Intern Med; 1990 Apr; 112(8):582-9. PubMed ID: 2109563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absence of biological effects of orally administered interferon-beta ser.
    Witt PL; Goldstein D; Storer BE; Grossberg SE; Flashner M; Colby CB; Borden EC
    J Interferon Res; 1992 Dec; 12(6):411-3. PubMed ID: 1289408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of combinations of interferon-beta ser and interferon-gamma on interferon-inducible proteins and on the cell cycle.
    Schiller JH; Horisberger MA; Bittner G; Carlin JM; Storer B; Byrne GI; Willson JK; Borden EC
    J Biol Response Mod; 1990 Aug; 9(4):368-77. PubMed ID: 2395002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pilot study of recombinant interferon beta (IFN-beta ser) in patients with recurrent glioma.
    Yung WK; Castellanos AM; Van Tassel P; Moser RP; Marcus SG
    J Neurooncol; 1990 Aug; 9(1):29-34. PubMed ID: 2082958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variation in the binding of 125I-labeled interferon-beta ser to cellular receptors during growth of human renal and bladder carcinoma cells in vitro.
    Ruzicka FJ; Schmid SM; Groveman DS; Cummings KB; Borden EC
    Cancer Res; 1987 Sep; 47(17):4582-9. PubMed ID: 2957045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II evaluation of recombinant interferon-beta (IFN-beta ser) in patients with diffuse mesothelioma: a Southwest Oncology Group study.
    Von Hoff DD; Metch B; Lucas JG; Balcerzak SP; Grunberg SM; Rivkin SE
    J Interferon Res; 1990 Oct; 10(5):531-4. PubMed ID: 2273299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/II trial of human recombinant beta-interferon serine in patients with renal cell carcinoma.
    Rinehart J; Malspeis L; Young D; Neidhart J
    Cancer Res; 1986 Oct; 46(10):5364-7. PubMed ID: 3756886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential induction of 2',5'-oligoadenylate synthetase by IFN-beta ser and IFN-alpha 2 in serum-supplemented and serum-free HL-60 leukemic cell cultures.
    Fraioli M; Wu JM
    J Biol Regul Homeost Agents; 1989; 3(3):112-7. PubMed ID: 2624146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.